China Sky One gets two product approvals

China Sky One Medical, a fully-integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, says that it recently obtained production approval from the State Food and Drug Administration for two of its newly-developed drugs.

The first, sodium ferulate by injection, is intended for the treatment of cardiovascular disease. It works by inhibiting the gathering of hematoblasts and stretches blood vessels in order to protect cardiac muscles. The other, doxofylline by injection, is intended for the treatment of asthma and bronchitis. It works on bronchia and relaxes bronchial smooth muscle in order to restrain asthma.

"We are very excited about our two new drugs and estimate that revenue from sodium ferulate will reach $1.0 million, and revenue from doxofylline will reach $500,000 once production starts in the beginning of 2009," said Yan-Qing Liu, chief executive of the firm.